Evidence map›Paper›PMID 37933736›Full record

ArticleJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism2024

Treatment with the vascular endothelial growth factor-A antibody, bevacizumab, has sex-specific effects in a rat model of mild traumatic brain injury.

Mujun Sun, Tamara L Baker, Campbell T Wilson, Rhys D Brady, Glenn R Yamakawa, David K Wright, Richelle Mychasiuk, Anh Vo, Trevor Wilson, Josh Allen and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Mujun SunDepartment of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia.
Tamara L BakerDepartment of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia.
Campbell T WilsonDepartment of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia.
Rhys D BradyDepartment of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia.
Glenn R YamakawaDepartment of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia.
David K WrightDepartment of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia.
Richelle MychasiukDepartment of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia.ORCID 0000-0001-5291-5083
Anh VoMonash Health Translation Precinct, Monash University, Melbourne, VIC, Australia.
Trevor WilsonMonash Health Translation Precinct, Monash University, Melbourne, VIC, Australia.
Josh AllenDepartment of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia.
Stuart J McDonaldDepartment of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia.
Sandy R ShultzDepartment of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia.ORCID 0000-0002-2525-8775
Monash University · AUMonash Health · AUVancouver Island University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mild traumatic brain injury (mTBI) involves damage to the cerebrovascular system. Vascular endothelial growth factor-A (VEGF-A) is an important modulator of vascular health and VEGF-A promotes the brain's ability to recover after more severe forms of brain injury; however, the role of VEGF-A in mTBI remains poorly understood. Bevacizumab (BEV) is a monoclonal antibody that binds to VEGF-A and neutralises its actions. To better understand the role of VEGF-A in mTBI recovery, this study examined how BEV treatment affected outcomes in rats given a mTBI. Adult Sprague-Dawley rats were assigned to sham-injury + vehicle treatment (VEH), sham-injury + BEV treatment, mTBI + VEH treatment, mTBI + BEV treatment groups. Treatment was administered intracerebroventricularly via a cannula beginning at the time of injury and continuing until the end of the study. Rats underwent behavioral testing after injury and were euthanized on day 11. In both females and males, BEV had a negative impact on cognitive function. mTBI and BEV treatment increased the expression of inflammatory markers in females. In males, BEV treatment altered markers related to hypoxia and vascular health. These novel findings of sex-specific responses to BEV and mTBI provide important insights into the role of VEGF-A in mTBI.

Indexed as

Brain ConcussionAnimalsBevacizumabDisease Models, AnimalFemaleMaleRatsRats, Sprague-DawleyVascular Endothelial Growth Factor ABevacizumabVascular Endothelial Growth Factor AAvastincognitionconcussionneuroinflammationVEGF-A antibody

Identifiers

PMID37933736
PMCPMC10981407
OpenAlexW4388455178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.